Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: DR Marco Gerlinger

Back to Search
( 2025 ) . Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy . Clinical & Experimental Immunology vol. 219 , ( 1 )
Ogden S, Metic N, Leylek O, Smith EA, Berner AM, Baker A-M, Uddin I, Buzzetti M et al. ( 2025 ) . Phenotypic heterogeneity and plasticity in colorectal cancer metastasis . Cell Genomics vol. 5 , ( 7 )
Bashir U, Wang C, Smillie R, Khan AKR, Ahmed HT, Ordidge K, Power N, Gerlinger M et al. ( 2025 ) . Deep learning for liver lesion segmentation and classification on staging CT scans of colorectal cancer patients: a multi-site technical validation study . Clinical Radiology vol. 85 ,
Savy T, Flanders L, Karpanasamy T ( 2025 ) . Cancer evolution: from Darwin to the Extended Evolutionary Synthesis . Trends in Cancer vol. 11 , ( 3 ) 204 - 215 .
Seyedi S, Harris VK, Kapsetaki SE, Narayanan S, Saha D, Compton Z, May A, Fakir E et al. ( 2024 ) . Resistance Management for Cancer: Lessons from Farmers . Cancer Research vol. 84 , ( 22 ) 3715 - 3727 .
Saeed A, Tabernero J, Parikh A, Van den Eynde M, Karthaus M, Wang G, Hecht JR ( 2024 ) . STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer . Future Oncology vol. 20 , ( 24 ) 1733 - 1743 .
Lane R, Mencel J, Turkes F, Challoner BR, McCafferty N, Ntellas P, Barber LJ, Rana I et al. ( 2024 ) . 124P Acquired resistance to first-line chemo- and EGFRab-therapy in mCRC: Biopsy analysis of the iSCORE trial . Annals of Oncology vol. 35 ,
Challoner BR, Slater SC, Sansano HB, Aresu M, Bryant A, Begum R, Rana T, Zhitkov O et al. ( 2024 ) . 30P Immunological markers of pathological and clinical and outcomes in mismatch repair deficient (MMRd) colorectal cancer (CRC) . Annals of Oncology vol. 35 ,
( 2024 ) . State of the art: Targeting microsatellite instability in gastrointestinal cancers . Critical Reviews in Oncology/Hematology vol. 199 ,
Buzzetti M, Gerlinger M ( 2023 ) . Assessing the toxicity of bispecific antibodies . Nature Biomedical Engineering vol. 8 , ( 4 ) 339 - 340 .
Newey A, Yu L, Barber LJ ( 2023 ) . Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ . Cancer Research Communications vol. 3 , ( 11 ) 2345 - 2357 .
Challoner BR, Woolston A, Lau D, Buzzetti M, Fong C, Barber LJ, Anandappa G, Crux R et al. ( 2023 ) . Genetic and immune landscape evolution in MMR‐deficient colorectal cancer . The Journal of Pathology vol. 262 , ( 2 ) 226 - 239 .
Mencel J, Turkes F, Barber L, Challoner B, Buzzetti M, Tran A, Chen H, McCafferty N et al. ( 2023 ) . P-111 PD1 and LAG3 inhibition as second+ line treatment after EGFR antibody-containing therapy in RAS/BRAF wildtype, MMRp metastatic colorectal cancer . Annals of Oncology vol. 34 , s53 - s54 .
( 2023 ) . Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer . Microbiome vol. 11 , ( 1 )
Gerlinger M, Gordon A, Barber LJ, Laliotis G, Athauda A, Challoner B, Woolston A, Mansukhani S et al. ( 2023 ) . Abstract 5591: Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma . Cancer Research vol. 83 , ( 7_Supplement ) 5591 - 5591 .
McCafferty N, Fong C, Barber LJ, Woolston A, Kleftogiannis D, Cromarty S, Kidd S, Begum R ( 2023 ) . Abstract 5593: Clonal mutation burden and evolutionary dynamics analysis in metastatic gastro-esophageal adenocarcinoma (GEA) by error corrected whole-exome circulating tumor DNA sequencing . Cancer Research vol. 83 , ( 7_Supplement ) 5593 - 5593 .
( 2023 ) . Impact of infiltrating T cell subtypes on survival and response to FLOT chemotherapy in resectable oesophagogastric adenocarcinoma (OGA) . Journal of Clinical Oncology vol. 41 , ( 4_suppl ) 443 - 443 .
( 2023 ) . Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA) . Journal of Clinical Oncology vol. 41 , ( 4_suppl ) 446 - 446 .
( 2022 ) . Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance . Journal of Cancer Research and Clinical Oncology vol. 149 , ( 2 ) 669 - 682 .
( 2022 ) . Advances in immunotherapy for MMR proficient colorectal cancer . Cancer Treatment Reviews vol. 111 ,
( 2022 ) . A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy . Genome Medicine vol. 14 , ( 1 )
Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Richtig G, Bracht JWP et al. ( 2022 ) . Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors . JCO Precision Oncology vol. 6 , ( 6 )
( 2022 ) . Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomes . Medical Oncology vol. 39 , ( 9 )
Challoner BR, Woolston A, Lau D, Buzzetti M, Barber LJ, Lund T, Sansano HB, von Loga K et al. ( 2022 ) . Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer . Cancer Research . vol. 82 , a002 - a002 .
Challoner BR, Woolston A, Lau D, Buzzetti M, Barber LJ, Lund T, Sansano HB, von Loga K et al. ( 2022 ) . Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer . Cancer Research . vol. 82 , pr012 - pr012 .
( 2022 ) . Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study . BJS Open vol. 6 , ( 1 )
Woolston A, Barber LJ, Griffiths B, Pich O, Lopez-Bigas N, Matthews N, Rao S, Watkins D et al. ( 2021 ) . Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer . Nature Ecology & Evolution vol. 5 , ( 7 ) 1024 - 1032 .
( 2021 ) . Identifying key questions in the ecology and evolution of cancer . Evolutionary Applications vol. 14 , ( 4 ) 877 - 892 .
( 2021 ) . Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough . Cancer Cell vol. 39 , ( 1 ) 16 - 18 .
Knebel FH, Barber LJ, Newey A, Kleftogiannis D, Woolston A, Fenwick K, Bettoni F, Ribeiro MFSA et al. ( 2020 ) . Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy . Cancers vol. 12 , ( 12 )
Khan K, Gonzalez-Exposito R, Cunningham D, Koh D-M, Woolston A, Barber L, Griffiths B, Kouvelakis K et al. ( 2020 ) . Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data . Frontiers in Oncology vol. 10 ,
( 2020 ) . Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk . European Radiology vol. 30 , ( 12 ) 6702 - 6708 .
( 2020 ) . Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer . European Journal of Cancer vol. 136 , 99 - 106 .
Masotti C, Knebel FH, Linck RDM, Lima J, Shimada AK, Alessi JV, Zucchetti BM, Gerlinger M et al. ( 2020 ) . Abstract A19: Detection of ESR1 mutations in plasma cell-free DNA from metastatic ER-positive breast cancer patients resistant to hormone therapy . Clinical Cancer Research vol. 26 , ( 11_Supplement ) a19 - a19 .
Challoner BR, von Loga K, Woolston A, Griffiths B, Sivamanoharan N, Semiannikova M, Newey A, Barber LJ et al. ( 2020 ) . Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes . Journal of the National Cancer Institute vol. 113 , ( 1 ) 88 - 98 .
( 2020 ) . Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study . ESMO Open vol. 5 , ( 1 )
( 2020 ) . SOlar: A translational phase II study of single-agent olaparib in the treatment of advanced esophagogastric cancer . Journal of Clinical Oncology vol. 38 , ( 4_suppl ) tps471 - tps471 .
von Loga K, Woolston A, Punta M, Barber LJ, Griffiths B, Semiannikova M, Spain G, Challoner B et al. ( 2020 ) . Author Correction: Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer . Nature Communications vol. 11 , ( 1 )
von Loga K, Woolston A, Punta M, Barber LJ, Griffiths B, Semiannikova M, Spain G, Challoner B et al. ( 2020 ) . Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer . Nature Communications vol. 11 , ( 1 )
( 2019 ) . Targeted drugs ramp up cancer mutability . vol. 366 , is. 6472 , pp. 1452 - 1453 . American Association for the Advancement of Science (AAAS)
Newey A, Griffiths B, Michaux J, Pak HS, Stevenson BJ, Woolston A, Semiannikova M, Spain G et al. ( 2019 ) . Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment . Journal for ImmunoTherapy of Cancer vol. 7 , ( 1 )
( 2019 ) . 661TiP iSCORE: Immunotherapy sequencing in colon and rectal cancer . Annals of Oncology vol. 30 ,
Davidson M, Mansukhani S, Starling N, Chau I, Watkins D, Cunningham D, Rao S, Lazaro-Alcausi R et al. ( 2019 ) . 674PD Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety run-in . Annals of Oncology vol. 30 ,
Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M et al. ( 2019 ) . Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer . Cancer Cell vol. 36 , ( 1 ) 35 - 50.e9 .
Davidson M, Barber LJ, Woolston A, Cafferkey C, Mansukhani S, Griffiths B, Moorcraft S-Y, Rana I et al. ( 2019 ) . Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma . Cancers vol. 11 , ( 5 )
Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Woolston A, Spain G, von Loga K, Challoner B et al. ( 2019 ) . CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids . Journal for ImmunoTherapy of Cancer vol. 7 , ( 1 )
Exposito RG, Semmianikova M, Griffiths B, Khan KH, Barber LJ, Woolston A, Spain G, von Loga K et al. ( 2019 ) . CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids . Journal of Clinical Oncology vol. 37 , ( 4_suppl ) 535 - 535 .
Mansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, Davidson M, Woolston A, Proszek PZ, Griffiths B et al. ( 2018 ) . Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing . Clinical Chemistry vol. 64 , ( 11 ) 1626 - 1635 .
( 2018 ) . Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience . Clinical Colorectal Cancer vol. 18 , ( 1 ) 64 - 71.e1 .
( 2018 ) . Metastasis Seeding Cells: Lone Invaders or Mass Migrators? . Clinical Cancer Research vol. 24 , ( 9 ) 2032 - 2034 .
( 2018 ) . Complications and seeding risk after percutaneous liver biopsy in an oncological setting . Journal of Clinical Oncology . vol. 36 , 246 - 246 .
( 2018 ) . Percutaneous radiofrequency versus microwave ablation for the treatment of colorectal liver metastases . Journal of Clinical Oncology . vol. 36 , 401 - 401 .
( 2018 ) . Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice . Annals of Oncology vol. 29 , ( 1 ) 230 - 236 .
( 2017 ) . Circulating tumour DNA, a promising biomarker for the management of colorectal cancer . Critical Reviews in Oncology/Hematology vol. 122 , 72 - 82 .
( 2017 ) . Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer . Gut vol. 67 , ( 1 )
( 2017 ) . Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study . Clinical Colorectal Cancer vol. 17 , ( 1 ) e69 - e76 .
Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M et al. ( 2017 ) . Classifying the evolutionary and ecological features of neoplasms . Nature Reviews Cancer vol. 17 , ( 10 ) 605 - 619 .
( 2017 ) . Cancer (r)evolution . Nature Ecology & Evolution vol. 1 , ( 8 ) 1051 - 1052 .
( 2017 ) . Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters . Annals of Oncology vol. 28 , ( 10 ) 2472 - 2480 .
Davies MN, Barber LJ, Spain G, Lopes F, Loga KV, Griffiths B, Woolston A, Alpar D et al. ( 2017 ) . Abstract 422: Lymph node metastasis evolution drives immune evasion and targeted therapy resistance in gastro-esophageal adenocarcinomas (GEAs) . Cancer Research . vol. 77 , 422 - 422 .
( 2017 ) . PD-015 Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in a predominanty gastrointestinal oncology patient population, treated at the Royal Marsden (RM) Hospital . Annals of Oncology vol. 28 ,
Gerber T, Barber L, Huetter S, Bogen D, Davies M, Assiotis I, Berneder M, Abbasi R et al. ( 2017 ) . Visualization of intra tumor heterogeneity by simultaneous analysis of tumor and liquid biopsy samples in stage M neuroblastomas . Klinische Pädiatrie . Conference: 30. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch-onkologische Forschung vol. 229 , 182 - 195 .
( 2016 ) . Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma . BMC Medicine vol. 14 , ( 1 )
( 2016 ) . A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result . Journal of Clinical Oncology . vol. 34 , 580 - 580 .
Lipinski KA, Barber LJ, Davies MN, Ashenden M ( 2016 ) . Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine . Trends in Cancer vol. 2 , ( 1 ) 49 - 63 .
Alpar D, Barber LJ ( 2015 ) . Genetic Intratumor Heterogeneity . Epigenetic Cancer Therapy ,
( 2015 ) . P-309 PROSPECT-R: A PROSPECTive translational study investigating molecular predictors of resistance and response to Regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (CRC) . Annals of Oncology . vol. 26 ,
( 2015 ) . Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome . Annals of Oncology vol. 26 , ( 5 ) 880 - 887 .
Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M et al. ( 2015 ) . SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair . Oncogene vol. 34 , ( 46 ) 5699 - 5708 .
( 2015 ) . Translating Seminoma Genomic Landscapes into Clinical Practice . European Urology vol. 68 , ( 1 ) 84 - 85 .
Davies MN, Alpar D, Griffiths B, Barber LJ, Lipinski KA, Eltahir Z, Wotherspoon A ( 2015 ) . Intratumor heterogeneity of DNA copy number aberrations in gastric and oesophageal adenocarcinomas . Journal of Clinical Oncology . vol. 33 , 78 - 78 .
Alpar D, Barber LJ ( 2015 ) . Chapter 24 Genetic Intratumor Heterogeneity . Epigenetic Cancer Therapy , Elsevier
Barber LJ, Davies MN ( 2014 ) . Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale . Current Opinion in Genetics & Development vol. 30 , 1 - 6 .
( 2014 ) . Spatial and temporal diversity in genomic instability processes defines lung cancer evolution . Science vol. 346 , ( 6206 ) 251 - 256 .
( 2014 ) . Cancer: Evolution Within a Lifetime . Annual Review of Genetics vol. 48 , ( 1 ) 1 - 22 .
( 2014 ) . The promise of circulating tumor cell analysis in cancer management . Genome Biology vol. 15 , ( 8 )
( 2014 ) . Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution . Genome Biology vol. 15 , ( 8 )
( 2014 ) . Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers . European Urology vol. 66 , ( 5 ) 936 - 948 .
( 2014 ) . Intratumour Heterogeneity in Urologic Cancers: From Molecular Evidence to Clinical Implications . European Urology vol. 67 , ( 4 ) 729 - 737 .
( 2014 ) . Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing . Nature Genetics vol. 46 , ( 3 ) 225 - 233 .
Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A et al. ( 2013 ) . The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer . Clinical Cancer Research vol. 19 , ( 24 ) 6924 - 6934 .
( 2013 ) . Computational optimisation of targeted DNA sequencing for cancer detection . Scientific Reports vol. 3 , ( 1 )
( 2013 ) . Ultra‐deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas . The Journal of Pathology vol. 231 , ( 4 ) 424 - 432 .
( 2013 ) . Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1 . The New England Journal of Medicine vol. 369 , ( 12 ) 1172 - 1173 .
( 2013 ) . Acquired resistance to crizotinib from a mutation in CD74-ROS1 . The New England journal of medicine vol. 369 , ( 12 )
( 2013 ) . Parallel evolution of tumour subclones mimics diversity between tumours . The Journal of Pathology vol. 230 , ( 4 ) 356 - 364 .
( 2013 ) . Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma . Journal of Clinical Oncology vol. 31 , ( 7 ) 971 - 972 .
( 2012 ) . The authors reply . New England Journal of Medicine vol. 366 , ( 22 )
( 2012 ) . Genome‐wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target . The Journal of Pathology vol. 227 , ( 2 ) 146 - 156 .
( 2012 ) . Intratumor Heterogeneity: Seeing the Wood for the Trees . Science Translational Medicine vol. 4 , ( 127 )
( 2012 ) . Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing . The New England Journal of Medicine vol. 366 , ( 10 ) 883 - 892 .
( 2010 ) . How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine . vol. 103 , is. 8 , pp. 1139 - 1143 . Springer Nature
Gerlinger M, Wilson P, Powles T, Shamash J ( 2010 ) . Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy . European Journal of Cancer vol. 46 , ( 16 ) 2913 - 2918 .
( 2010 ) . Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets . Genome Medicine vol. 2 , ( 8 )
( 2010 ) . Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference . European Journal of Cancer vol. 46 , ( 12 ) 2166 - 2177 .
( 2010 ) . Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials . The Lancet Oncology vol. 11 , ( 4 ) 358 - 365 .
Gerlinger M, Rohatiner AZS, Matthews J, Davies A, Lister TA, Montoto S ( 2010 ) . Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management . Haematologica vol. 95 , ( 7 ) 1130 - 1135 .
( 2009 ) . 951 ESTABLISHED PROGNOSTIC MODELS FAIL TO PREDICT THE OUTCOME OF DOSE DENSE CHEMOTHERAPY FOR THE TREATMENT OF RECURRENT GERM CELL TUMOURS (GCTS) . European Urology Open Science vol. 8 , ( 4 )
Gerlinger M, Matthews J, Davies A, Lister TA, Montoto S, Rohatiner AZS ( 2008 ) . Active Surveillance Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma . Blood vol. 112 , ( 11 )
( 2008 ) . Non-castrate status at the end of chemotherapy for metastatic hormone-resistant prostate cancer (HRPC) correlates with a better overall survival . Journal of Clinical Oncology vol. 26 , ( 15_suppl ) 16102 - 16102 .
( 2006 ) . Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients . The Journal of Immunology vol. 177 , ( 11 ) 8212 - 8218 .
( 2005 ) . Egr-1 Induces the Expression of Its Corepressor Nab2 by Activation of the Nab2 Promoter Thereby Establishing a Negative Feedback Loop* . Journal of Biological Chemistry vol. 280 , ( 52 ) 42785 - 42793 .
Khan K, exposito RG, Cunningham D, Koh D-M, Woolston A, Barber L, Griffins B, Kouvelakis K et al. . Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in Oncology patients treated in a specialist cancer centre with prospective validation within clinical trial data .
von Loga K, Woolston A, Punta M, Barber L, Griffiths B, Semiannikova M, Spain G, Challoner B et al. . Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer .
Challoner BR, Woolston A, Lau D, Buzzetti M, Fong C, Barber LJ, Anandappa G, Crux R et al. . Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer .
Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Exposito RG, Patil Y, Mansukhani S et al. . Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer .
Newey A, Yu L, Barber LJ, Choudhary JS, Bassani-Sternberg M, Gerlinger M . Multifactorial remodeling of the cancer immunopeptidome by interferon gamma .
Woolston A, Barber LJ, Griffiths B, Matthews N, Rao S, Watkins D, Chau I, Starling N et al. . Mutational processes impact the evolution of anti-EGFR antibody resistance in colorectal cancer .
Mansukhani S, Barber LJ, Moorcraft SY, Davidson M, Woolston A, Griffiths B, Fenwick K, Herman B et al. . Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error corrected circulating tumour DNA sequencing .
Back to Search